Jazz Entered into a License Agreement with Werewolf to Develop WTX-613 for the Treatment of Cancer Using PREDATOR Protein Engineering Technology
Shots:
- Werewolf to receive $15M up front &~$1.26B in milestones along with royalties. Jazz obtains exclusive development & commercialization rights globally to WTX-613 & is expected to submit an IND application to the US FDA in 2023
- WTX-613 is being studied in preclinical development & minimizes the sev. toxicities that have been observed with systemically active recombinant IFNα therapy & maximize clinical benefit when administered as monothx. or in combination with other agents
- Jazz will advance its oncology pipeline to deliver novel therapies along with the immuno-oncology program & also plans to deliver 5 additional novel therapies to patients at the end of the decade as part of Vision 2025
Ref: PR Newswire | Image: Jazz
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
